KSQ Therapeutics, Inc.

KSQ Therapeutics, Inc. is a biotechnology company specializing in developing innovative therapies for human diseases using their proprietary CRISPRomics® platform, aimed at advancing cancer treatment through genomic manipulation. Founded in 2015 and headquartered in Cambridge, US, KSQ Therapeutics focuses on innovative cancer therapies. In September 2018, the company completed a Series C funding round raising USD 80 mn, participated by notable investors including ARCH Venture Partners and Baillie Gifford.

The firm has completed two significant funding deals to date. KSQ Therapeutics focuses on developing innovative therapies targeting human diseases, particularly through their proprietary CRISPRomics® platform. This platform is designed to identify and manipulate the genome's therapeutic targets with potential curative effects. The company’s key offerings include CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®), which represent a promising approach in cancer treatment by harnessing the body's immune system to attack tumors.

These products aim to address complex medical challenges, primarily in the oncology sector, and are intended for use by healthcare providers and clinical research institutions. KSQ Therapeutics operates globally, with its products potentially reaching markets in North America, Europe, and Asia, catering to oncologists, hospitals, and research facilities. KSQ Therapeutics generates revenue primarily through partnerships and collaborations with other biotechnology firms and healthcare organizations. The company engages in transactions involving research agreements and development collaborations, providing access to its CRISPRomics® platform and eTIL® programs for cancer treatment.

These agreements often include milestone payments tied to the progress of the therapeutic candidates, as well as potential royalties on future sales of successful products. The business structure emphasizes B2B relationships, targeting pharmaceutical companies eager to leverage KSQ’s proprietary technology. Pricing details for specific services or partnerships are established on a case-by-case basis, reflecting the unique value and advancements associated with KSQ's proprietary offerings. KSQ Therapeutics plans to utilize the USD 80 mn raised in their Series C funding round in September 2018 to further develop their CRISPRomics® technology and eTIL® therapies.

The company is focusing on launching new products aimed at oncology treatment solutions and expanding into additional markets in Europe and Asia by 2025. This strategic funding will support research and development efforts to enhance product offerings and solidify their presence in targeted global markets.